KRMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KRMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
KORU Medical Systems's EBITDA per Share for the three months ended in Jun. 2024 was $-0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of KORU Medical Systems was 180.20% per year. The lowest was -91.30% per year. And the median was 16.70% per year.
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
KORU Medical Systems (NAS:KRMD) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of KORU Medical Systems's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Manko Joseph M. Jr. | 10 percent owner | 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103 |
Kenneth E Miller | officer: Chief Commercial Officer | 26 MOUNTAINVIEW RD, WARREN NJ 07059 |
Edward Wholihan | director | C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
Linda M Tharby | officer: President and CEO | BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Robert Cascella | director | C/O HOLOGIC, INC., BEDFORD MA 01730 |
Lafrence Andrew D.c. | officer: Chief Financial Officer | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Thomas Edward Adams | officer: Interim CFO | 524 WOODLAND AVENUE, BRIELLE NJ 08730 |
Brian Case | officer: Chief Technology Officer | 424 CYPRUS CIR, LAKE VILLA IL 60046-8629 |
Shahriar Matin | director | 96 TALAMINE COURT, COLORADO SPRINGS CO 80907 |
Donna French | director | 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010 |
Donald B Pettigrew | officer: Pres./Chief Commercial Officer | 7871 ENGEN LOOP, PARK CITY UT 84098 |
Karen Fisher | officer: CFO | 24 CARPENTER ROAD, CHESTER NY 10918 |
Daniel S Goldberger | director | 24 CARPENTER ROAD, CHESTER NY 10918 |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Horton Freedom, L.p. | 10 percent owner | 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103 |
From GuruFocus
By GuruFocus Research • 05-01-2024
By Business Wire • 03-18-2024
By Business Wire • 11-07-2023
By Business Wire • 11-28-2023
By Business Wire • 08-07-2024
By Business Wire • 07-02-2024
By Business Wire • 03-11-2024
By Business Wire • 06-04-2024
By GuruFocus Research • 11-08-2023
By GuruFocus Research • 05-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.